Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) shot up 3.2% during trading on Friday . The company traded as high as $152.50 and last traded at $151.51, with a volume of 228,197 shares. The stock had previously closed at $146.82.

A number of equities research analysts recently issued reports on the stock. Wedbush restated an “outperform” rating and issued a $239.00 target price on shares of Intercept Pharmaceuticals in a report on Monday, July 25th. Barclays PLC restated a “buy” rating and issued a $205.00 target price (up from $200.00) on shares of Intercept Pharmaceuticals in a report on Wednesday, June 1st. Vetr upgraded shares of Intercept Pharmaceuticals from a “buy” rating to a “strong-buy” rating and set a $146.64 target price for the company in a report on Monday, May 16th. Robert W. Baird restated a “buy” rating on shares of Intercept Pharmaceuticals in a report on Sunday, May 8th. Finally, FBR & Co restated a “hold” rating and issued a $200.00 target price (up from $192.00) on shares of Intercept Pharmaceuticals in a report on Tuesday, May 31st. Five analysts have rated the stock with a sell rating, five have issued a hold rating and ten have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $177.67.

The company’s market cap is $3.73 billion. The stock’s 50 day moving average is $159.27 and its 200-day moving average is $143.85.

Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($3.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.69) by $0.55. The company earned $5.52 million during the quarter, compared to analysts’ expectations of $1.72 million. Intercept Pharmaceuticals’s revenue for the quarter was up 1140.4% compared to the same quarter last year. During the same period last year, the company earned ($1.99) earnings per share. Equities analysts predict that Intercept Pharmaceuticals Inc. will post ($16.31) EPS for the current fiscal year.

In related news, insider Lisa Bright sold 246 shares of the stock in a transaction that occurred on Thursday, August 25th. The stock was sold at an average price of $159.00, for a total value of $39,114.00. Following the transaction, the insider now owns 18,460 shares in the company, valued at $2,935,140. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Mark Pruzanski sold 714 shares of the stock in a transaction that occurred on Tuesday, July 5th. The shares were sold at an average price of $145.11, for a total value of $103,608.54. The disclosure for this sale can be found here.

A hedge fund recently raised its stake in Intercept Pharmaceuticals stock. BlackRock Advisors LLC increased its stake in shares of Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) by 5.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 125,274 shares of the biopharmaceutical company’s stock after buying an additional 6,461 shares during the period. BlackRock Advisors LLC owned 0.51% of Intercept Pharmaceuticals worth $18,710,000 at the end of the most recent reporting period.

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.